Trial Profile
Amrubicin at a dose of 45mg/m2 with pegylated granulocyte-colony stimulating factor support in patients with previously treated small-cell lung cancer - A prospective observational study -
Status:
Not yet recruiting
Phase of Trial:
Phase IV
Latest Information Update: 08 Nov 2018
Price :
$35
*
At a glance
- Drugs Amrubicin (Primary) ; Pegfilgrastim
- Indications Small cell lung cancer
- Focus Therapeutic Use
- 08 Nov 2018 New trial record